Loading...
Loading...
Piper Jaffray is out with its report today on Tengion
TNGN, maintaining Overweight.
In a note to clients, Piper Jaffray writes, "We maintain our Overweight rating and $3.50 price target awaiting further clinical update on the Neo-Urinary Conduit study. Our target is based on a projected EV of $88 million plus YE:11E net cash $6 million."
Shares of TNGN closed Monday at $1.17, up 3.40% from Friday's close.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in